H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $69 from $64 and keeps a Buy rating on the shares. The firm says the company’s “solid” Q3 yielded top- and bottom-line outperformance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals’ Common Stock Faces Risks from Convertible Preferred Stock Supremacy
- Rhythm Pharmaceuticals price target raised to $80 from $77 at Canaccord
- Rhythm Pharmaceuticals price target raised to $65 from $55 at TD Cowen
- Rhythm Pharmaceuticals Reports Strong Q3 Revenue Growth
- Rhythm Pharmaceuticals reports Q3 EPS (73c), consensus (80c)
Questions or Comments about the article? Write to editor@tipranks.com